UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (date of earliest event reported):October 19, 2018
Nexien BioPharma, Inc.
(Exact name of registrant as specified in its charter)
Commission File No.: 0-55320
| Delaware | | 26-2049376 |
| (State or other jurisdiction of incorporation) | | (I.R.S. Employer Identification No.) |
| | | |
| 4340 E Kentucky Ave, Suite 206, Glendale, CO | | 80246 |
| (Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (303) 495-7583
Intiva BioPharma Inc.
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| [ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | |
| [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | |
| [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | |
| [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company [X]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item 8.01 Other Events.
Effective October 19, 2018, the common stock of the registrant, Nexien BioPharma, Inc., will trade under the symbol, “NXEN.” The new CUSIP number for the common stock is 65343D100. A press release announcing the new trading symbol is included as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| NEXIEN BIOPHARMA, INC. | |
| | |
| /s/: Alain Bankier | |
| Alain Bankier, Chief Executive Officer | |
| October 19, 2018 | |
EXHIBIT INDEX
